First Data On Amphibia Inventory And Distribution (Ordre Des Anoura) In Northwestern Algeria (Tiaret Area)

In the northwest of Algeria, we find the Tiaret area, which is characterized by a remarkable diversity of ecosystems, mainly composed of forests, scrub, cereal plain, steppe, a dune corridor, wetlands, Chott, Daya, dams, reservoirs of hill waters, ponds, wadis and cliffs. This diversity provides favorable and essential conditions for various species of amphibians that frequent this area with a semiarid climate. The present work aims to carry out an inventory of amphibians in the Tiaret region, as well as their distributions in these various ecosystems. We were able to inventory around 05 species of amphibians, distributed among 04 families and 01 order, distributed, in the different remarkable areas of the study region. Most of the species are frequent and abundant, cited in the bibliography (Pelophylax saharicus, Bufotes boulengeri, Sclerophrys mauritanica and Discoglossus pictus); except for one species (Hyla meridionalis), which is very rare in our study area

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

International audienceBackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (<50 copies/mL) before 14 weeks of gestation (WG) while on rilpivirine, we compared the probability of viral rebound (≥50 copies/mL) during pregnancy between subjects continuing rilpivirine versus those switching to RFC.ResultsAmong 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was <50 copies/mL in 95.6% of women. Among 69 women with documented viral suppression before 14 WG, the risk of viral rebound was higher when switching to RFCs than when continuing rilpivirine (20.0% versus 0.0%, P = 0.046). Delivery outcomes were similar between groups (overall birth defects, 3.8/100 live births; pregnancy losses, 2.0%; preterm deliveries, 10.6%). No HIV transmission occurred.ConclusionsIn virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes